Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Mai 2026 09:00 ET | Quelle: Oncolytics Biotech, Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
21. Mai 2026 17:00 ET | Quelle: Compass Therapeutics

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with...
21. Mai 2026 08:00 ET | Quelle: Society for Industrial and Applied Mathematics

SIAM Announces Dr. Magnus Fontes as 2026 I. E. Block Community Lecture Speaker

Philadelphia, PA, May 21, 2026 (GLOBE NEWSWIRE) -- Dr. Magnus Fontes, Institut Roche and Lund University, will deliver the 2026 I. E. Block Community Lecture. He will be presenting at the 2026 SIAM...
20. Mai 2026 11:07 ET | Quelle: MiNK Therapeutics

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved...
19. Mai 2026 04:34 ET | Quelle: Research and Markets

Immunology Collaboration and Licensing Agreements Benchmark Report 2026: Access to 864 Deals, Delivering a Clear and Evidence-based View of How Partnerships are Designed, Negotiated, and Executed

Dublin, May 19, 2026 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2018-2026" report has been added to ResearchAndMarkets.com's offering.The definitive benchmark for...
15. Mai 2026 07:00 ET | Quelle: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ...
11. Mai 2026 04:00 ET | Quelle: Anaveon

Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio

Anaveon announces presentation of positive ANV600 Clinical Data at ASCO 2026 and actively seeks partners for its legacy Oncology Portfolio.
07. Mai 2026 20:44 ET | Quelle: Odyssey Therapeutics Inc

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.
07. Mai 2026 01:05 ET | Quelle: Pharming Group N.V.

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Pharming today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS) in New Orleans, LA.
06. Mai 2026 07:00 ET | Quelle: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...

Nächste Seite